We could not find any results for:
Make sure your spelling is correct or try broadening your search.
BriaCell Therapeutics Corp is an immuno-oncology focused biotechnology company developing targeted and safe approaches for the management of cancer. BriaCell, in collaboration with Incyte Corp., is conducting a Phase I/IIa clinical trial of Bria-IMT, its lead candidate, in a Combination Study with I... BriaCell Therapeutics Corp is an immuno-oncology focused biotechnology company developing targeted and safe approaches for the management of cancer. BriaCell, in collaboration with Incyte Corp., is conducting a Phase I/IIa clinical trial of Bria-IMT, its lead candidate, in a Combination Study with Incyte drugs, INCMGA00012, and epacadostat, in advanced breast cancer. Additionally, it is developing Bria-OTS, off-the-shelf personalized immunotherapy, for advanced breast cancer. Bria-OTS immunotherapy treatments are personalized to match the patient without the need for personalized manufacturing and is designed to produce a potent and selective immune response against the cancer of each patient eliminating the time, expense and complex manufacturing logistics associated with immunotherapies. Show more
BriaCell doubles Progression-Free-Survival (PFS) and Clinical Benefit Rate vs historical results in the literatureBria-IMTβ’ PFS compares favorably to PFS of most recent treatment in 48% of...
PHILADELPHIA and VANCOUVER, British Columbia, May 30, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW) (TSX: BCT) (βBriaCellβ or the βCompanyβ), a clinical-stage...
Study to evaluate the effects of Bria-OTSβ’ in combination with anti-PD-1 antibody tislelizumab, in advanced, late stage, heavily pretreated metastatic breast cancer. PHILADELPHIA and VANCOUVER...
83% intracranial objective response rate (iORR) with Bria-IMTβ’ in heavily pretreated advanced breast cancer patients with CNS metastasesMedian progression free survival (PFS) of 4.1 months in ADC...
PHILADELPHIA and VANCOUVER, British Columbia, May 17, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (βBriaCellβ or the βCompanyβ), a clinical-stage...
PHILADELPHIA and VANCOUVER, British Columbia, May 15, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (βBriaCellβ or the βCompanyβ), a clinical-stage...
Oral presentation by Mayo Clinic Professor and Principal Investigator, Saranya Chumsri, MDTwo poster presentations include Drs. Hurvitz (Fred Hutchinson Cancer Center), Brufsky (UPMC), and...
Preclinical data shows that BriaCellβs Bria-OTS+β’ and Bria-PROS+β’ effectively induce an anti-cancer immune response via multiple mechanisms including naΓ―ve helper and killer T cells, dendritic...
PFS of 4.2 months in Phase 2 ADC resistant patients receiving Bria-IMTβ’ pivotal Phase 3 formulation is twice that of controls in similar studies PFS results reinforced by larger number of prior...
Agreement with a leading cancer treatment group to advance the clinical development of Bria-OTS+ (breast cancer) and Bria-PROS+ (prostate cancer), BriaCellβs novel off-the-shelf personalized...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.08 | 5.51724137931 | 1.45 | 1.75 | 1.3178 | 148143 | 1.58968385 | CS |
4 | -0.75 | -32.8947368421 | 2.28 | 2.44 | 1.2699 | 227913 | 1.5009498 | CS |
12 | -1.42 | -48.1355932203 | 2.95 | 3.04 | 1.2699 | 123271 | 1.92458366 | CS |
26 | -3.96 | -72.131147541 | 5.49 | 5.97 | 1.2699 | 111500 | 3.0570829 | CS |
52 | -4.55 | -74.8355263158 | 6.08 | 7.59 | 1.2699 | 101886 | 4.31203846 | CS |
156 | -4.76 | -75.6756756757 | 6.29 | 12.47 | 1.2699 | 664465 | 7.0792561 | CS |
260 | -2.71 | -63.9150943396 | 4.24 | 12.47 | 1.2699 | 868052 | 6.58375301 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions